BR112018010812A2 - compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer - Google Patents

compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer

Info

Publication number
BR112018010812A2
BR112018010812A2 BR112018010812A BR112018010812A BR112018010812A2 BR 112018010812 A2 BR112018010812 A2 BR 112018010812A2 BR 112018010812 A BR112018010812 A BR 112018010812A BR 112018010812 A BR112018010812 A BR 112018010812A BR 112018010812 A2 BR112018010812 A2 BR 112018010812A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
thiadiazole compounds
methoxy
hydrogen
compound
Prior art date
Application number
BR112018010812A
Other languages
English (en)
Portuguese (pt)
Inventor
Matthew Wood James
Wilhelmus Maria Nissink Johannes
David Charles Mark
Raymond Verschoyle Finlay Maurice
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of BR112018010812A2 publication Critical patent/BR112018010812A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112018010812A 2015-11-30 2016-11-30 compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer BR112018010812A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
BR112018010812A2 true BR112018010812A2 (pt) 2018-11-27

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010812A BR112018010812A2 (pt) 2015-11-30 2016-11-30 compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer

Country Status (25)

Country Link
US (1) US9938265B2 (https=)
EP (1) EP3383871B1 (https=)
JP (1) JP6873132B2 (https=)
KR (1) KR20180083412A (https=)
CN (1) CN108349967B (https=)
AR (1) AR106876A1 (https=)
AU (1) AU2016363719B2 (https=)
BR (1) BR112018010812A2 (https=)
CA (1) CA3005516C (https=)
CL (1) CL2018001408A1 (https=)
CO (1) CO2018006929A2 (https=)
DK (1) DK3383871T3 (https=)
DO (1) DOP2018000134A (https=)
EA (1) EA201891240A1 (https=)
ES (1) ES2759940T3 (https=)
IL (1) IL258644A (https=)
MX (1) MX2018006528A (https=)
NI (1) NI201800065A (https=)
PE (1) PE20181450A1 (https=)
PH (1) PH12018501132A1 (https=)
SG (1) SG11201803813UA (https=)
SV (1) SV2018005701A (https=)
TN (1) TN2018000126A1 (https=)
TW (1) TW201730188A (https=)
WO (1) WO2017093300A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
AU2019363115B2 (en) 2018-10-16 2021-12-09 Medshine Discovery Inc. Thiadiazole derivative and uses thereof as a GLS1 inhibitor
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038332A1 (en) * 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
SI2421826T1 (sl) * 2009-04-20 2014-02-28 F. Hoffmann-La Roche Ag Derivati prolina kot inhibitorji katepsina
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
BR112015010955A2 (pt) * 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CA2934700A1 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
EP3116872A4 (en) * 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
CA3005516C (en) 2024-04-16
TN2018000126A1 (en) 2019-10-04
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
JP2019501134A (ja) 2019-01-17
US20170152254A1 (en) 2017-06-01
SG11201803813UA (en) 2018-06-28
SV2018005701A (es) 2018-11-27
AU2016363719A1 (en) 2018-07-05
NI201800065A (es) 2018-10-18
CN108349967A (zh) 2018-07-31
IL258644A (en) 2018-06-28
ES2759940T3 (es) 2020-05-12
ES2759940T8 (es) 2020-05-20
JP6873132B2 (ja) 2021-05-19
CL2018001408A1 (es) 2018-10-12
AU2016363719B2 (en) 2019-11-14
EA201891240A1 (ru) 2018-11-30
CN108349967B (zh) 2022-02-15
EP3383871B1 (en) 2019-09-11
DOP2018000134A (es) 2018-06-30
AR106876A1 (es) 2018-02-28
CO2018006929A2 (es) 2018-10-10
PE20181450A1 (es) 2018-09-12
CA3005516A1 (en) 2017-06-08
AU2016363719A8 (en) 2018-07-12
KR20180083412A (ko) 2018-07-20
PH12018501132A1 (en) 2019-01-21
MX2018006528A (es) 2019-05-15
DK3383871T3 (da) 2019-12-16
EP3383871A1 (en) 2018-10-10
TW201730188A (zh) 2017-09-01

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
MX391812B (es) Agonista fxr derivado de esteroides.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
UA111382C2 (uk) Інгібітори протеїнкінази
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201690127A1 (ru) Состав на основе ингибиторов syk
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
SG10201804026WA (en) Inhibitors of influenza viruses replication
BR112018010812A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
BR112018010806A2 (pt) compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX378509B (es) Compuesto de pirimidina y su uso farmaceutico.
EA201692470A1 (ru) Фармацевтические комбинации
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
EA201591649A1 (ru) Составы с органическими соединениями
MX2018006374A (es) Compuestos de bis-piridazina y su uso en el tratamiento del cancer.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
MX387820B (es) Composición farmacéutica y métodos de usos.
MX389613B (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]